Theravance Biopharma (TBPH) Change in Account Payables (2013 - 2026)
Theravance Biopharma (TBPH) posted quarterly Change in Account Payables of -$1.5 million for Q1 2026, down 984.34% year-over-year from $166000.0 in Q1 2025, and down 513.52% quarter-over-quarter from $355000.0 in Q4 2025.
Powered by 
Analysis
Theravance Biopharma (TBPH) Change in Account Payables (2013 - 2026) Analysis & Trends
Theravance Biopharma (TBPH) has reported Change in Account Payables for 14 consecutive years, with -$1.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Account Payables fell 984.34% year-over-year to -$1.5 million; the TTM figure through Mar 2026 stood at -$1.3 million (down 278.69% YoY), while the FY2025 annual figure was $326000.0, down 56.53% from the prior year.
- Change in Account Payables eased to -$1.5 million in Q1 2026 per TBPH's latest filing, from $355000.0 in the prior quarter.
- Across five years, Change in Account Payables topped out at $2.2 million in Q3 2022 and bottomed at -$3.8 million in Q4 2022.
- Historically, Change in Account Payables has averaged -$117529.4 across 5 years, with a median of $166000.0 in 2025.
- On a YoY basis, Change in Account Payables climbed as much as 344.55% in 2025 and fell as far as 36550.0% in 2025.
- Theravance Biopharma's Change in Account Payables stood at -$3.8 million in 2022, then soared by 90.75% to -$348000.0 in 2023, then jumped by 326.44% to $788000.0 in 2024, then slumped by 54.95% to $355000.0 in 2025, then tumbled by 513.52% to -$1.5 million in 2026.
- Business Quant data shows TBPH's Change in Account Payables at -$1.5 million in Q1 2026, $355000.0 in Q4 2025, and $538000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -8.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 5.03 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 37.53 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Theravance Biopharma | 882.99 Mn | 495.33 Mn | - | -448,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -448,000.00 |
| Mar 31, 2026 | -1.47 Mn |
| Dec 31, 2025 | 355,000.00 |
| Sep 30, 2025 | 538,000.00 |
| Jun 30, 2025 | -733,000.00 |
| Mar 31, 2025 | 166,000.00 |
| Dec 31, 2024 | 788,000.00 |
| Sep 30, 2024 | -220,000.00 |
| Jun 30, 2024 | -2,000.00 |
| Mar 31, 2024 | 184,000.00 |
| Dec 31, 2023 | -348,000.00 |
| Sep 30, 2023 | 271,000.00 |
| Jun 30, 2023 | -919,000.00 |
| Mar 31, 2023 | 1.00 Mn |
| Dec 31, 2022 | -3.76 Mn |
| Sep 30, 2022 | 2.18 Mn |
| Jun 30, 2022 | 1.59 Mn |
| Mar 31, 2022 | -1.62 Mn |
| Dec 31, 2021 | -5.74 Mn |
| Sep 30, 2021 | -1.82 Mn |